Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$2.97
-2.1%
$3.57
$2.11
$12.60
$5.55M0.03475,356 shs4,330 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.43
-1.2%
$13.16
$1.10
$15.85
$21.57M1.252,160 shs1,877 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.50
+4.3%
$2.44
$1.87
$4.20
$20.94M120,522 shs14,923 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.44
+0.6%
$3.16
$2.57
$6.88
$21.44M0.639,025 shs3,426 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-2.15%-4.66%-24.55%-53.67%-52.94%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-1.24%-1.96%-0.36%-1.96%+949.38%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
+4.33%+1.79%-4.79%+9.82%-24.12%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.56%+0.56%+3.90%-4.87%-44.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.2787 of 5 stars
0.05.00.04.30.01.70.0
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.3798 of 5 stars
0.03.00.00.00.01.70.6
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
2.3457 of 5 stars
3.53.00.00.01.70.01.3
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6823 of 5 stars
0.03.00.00.01.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
3.00
Buy$15.00499.04% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.33M4.21N/AN/A($11.37) per share-0.26
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$110K196.11N/AN/A$14.25 per share0.94
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1M21.58N/AN/A$3.49 per share0.72
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$7.90M-$19.96N/AN/A-647.29%N/A-50.13%8/18/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest ALBT, FNCH, LSTA, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$1.43N/A-$1.43N/AN/A
5/8/2025Q1 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.53-$0.55-$0.02-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.19
0.19
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
7.52
7.52
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million1.19 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
308.62 million7.79 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

(NAII) Trading Advice
(NAII) Pivots Trading Plans and Risk Controls

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$2.96 -0.07 (-2.15%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$3.00 +0.04 (+1.32%)
As of 06/18/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.43 -0.17 (-1.24%)
As of 06/18/2025 11:52 AM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$2.52 +0.13 (+5.21%)
As of 06/18/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.44 +0.02 (+0.56%)
Closing price 06/18/2025 03:58 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 06/18/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.